High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: A 10-year experience

Bone Marrow Transplantation

Volumn 21, Issue 2, 1998, Pages 127-132

  Laportm, G F ^a,d   Grad, G ^b   Grinblatt, D L ^a   Bitran, J D ^c   Williams, S F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Northwest Oncol/Hematology Assoc   (United States)

^c Cancer Care Center   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Bone marrow transplantation; Breast cancer; Carmustine; Cyclophosphamide; High dose chemotherapy; Thiotepa

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION;

EID: 0031983478     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701066     Document Type: Article

References (34)

1. Wingo PA, Tong T, Bolden S. Cancer statistics: 1995. Cancer J Clin 1995; 48: 8-30.
2. Clark GM, Sledge GW, Osborne KC, McGuire WL. Survival from first recurrence; relative importance of prognostic factors in 1105 breast cancer patients. J Clin Oncol 1986; 4: 1162-1170.
3. Mick R, Begg C, Antman K et al. Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Treat Res 1989; 13: 33-38.
4. Myers SE, Williams SF. Role of high-dose chemotherapy and autologous stem cell support in the treatment of breast cancer. Hematol Oncol Clin N Amer 1993; 7: 631-645.
5. Ayash LJ, Wheeler C, Fairclough D et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043-2049.
6. Kennedy MJ, Beveridge RA, Rowley SD et al. High dose chemotherapy with reinfusion of purged autologous bone marrow following dose intensive induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991; 83: 920-926.
7. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with auto-logous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-110.
8. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-1288.
9. Hryniuk WM, Levine MM, Levin L. Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. NCI Monogr 1986; 1: 87-94.
10. Elias AD, Ayash L, Anderson KC et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79: 3036-3044.
11. Crilley P, Goldstein LJ. Peripheral blood stem cell transplant in breast cancer. Semin Oncol 1995; 3: 238-249.
12. Williams SF, Mick R, Desser R et al. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 1989; 7: 1824-1830.
13. Williams SF, Gilewski T, Mick R, Bitran JD. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 1992; 10: 1743-1747.
14. Myers SE, Williams SF, Geller RB. Cyclophosphamide mobilization of peripheral blood stem cells for use in autologous transplantation after high-dose chemotherapy: clinical results in patients with contaminated or hypocellular bone marrow. J Hematother 1992; 1: 27-33.
15. Mundt AJ, Sibley GS, Williams SF et al. Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy. Int J Radiation Oncol Biol Phys 1994: 30: 151-160.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
18. Holland HK, Dix SP, Geller RB et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa and carboplatin plus auto-logous marrow/stem cell transplantation and comprehensive supportive care. J Clin Oncol 1996; 14: 1156-1164.
19. Mulder NH, Mulder PO, Sleijfer DT et al. Induction chemotherapy and intensification with autologous bone marrow reinfusion in patients with locally advanced and disseminated breast cancer. Eur J Cancer 1993; 29A: 668-671.
20. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-2489.
21. Greenberg AC, Hortobagyi GN, Smith TL et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J clin Oncol 1996; 14: 2197-2205.
22. Leone BA, Romero A, Rabinovich MG et al. Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis. Am J Clin Oncol 1988; 11: 618-622.
23. Perez JE, Machiavelli M, Leone BA et al. Bone-only versus visceral only metastatic pattern in breast cancer: analysis of 150 patients. Am J Clin Oncol 1990; 13: 294-298.
24. Sherry MM, Greco FA, Johnson DH et al. Metastatic breast cancer confined to the skeletal system. Am J Med 1986; 81: 381-386.
25. Brown ER, Sridhara R, Sledge GW et al. Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol 1995; 13: 2050-2055.
26. Ayash LJ, Elias A, Wheeler C et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer. J Clin Oncol 1994; 12: 37-44.
27. Dunphy ER, Spitzer G, Fornoff JE et al. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 1994; 73: 2157-2167.
28. Ross AA, Cooper BW, Lazarus HM et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605-2610.
29. Rill DR, Santana VM, Roberts WM et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994; 84: 380-383.
30. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
31. Williams SF, Lee WJ, Bender JG et al. Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer. Blood 1996; 87: 1687-1691.
32. Shpall EJ, Bast RC, Joines WT et al. lmmunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 1991; 7: 145-151.
33. Fields KK, Elfenbein GJ, Trudeau WL et al. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1868-1876.
34. Stadtmauer E, Sickles C, Mangan P et al. Tumor contamination of stem cells and prognosis with G-CSF mobilized peripheral stem cell transplant for responding metastatic breast cancer. J Clin Oncol 1996; 15: 339 (Abstr. 981).